To determine whether the effects of platelet activating factor on the airways may be due to the production of leukotrienes we studied the effects of pretreatment with the selective cysteinyl leukotriene antagonist SK&F 12-6 (-23-8, -14) for sGaw and -12-5, (-20-8 -4 2) for PVmax30. The mean % fall in neutrophil count was similar after SK&F 104353-Z2 (46%) and after placebo (50%) (95% CL of difference 13-6, 6 6). Bronchial responsiveness to methacholine did not increase above baseline values in any subject when measured two weeks after challenge by platelet activating factor. This study suggests that leukotrienes play a part in the response to platelet activating factor in man.
D A Spencer, J M Evans, S E Green, P J Piper, J F Costello Abstract To determine whether the effects of platelet activating factor on the airways may be due to the production of leukotrienes we studied the effects of pretreatment with the selective cysteinyl leukotriene antagonist SK&F 104353-Z2 on the airway and cellular responses to inhaled platelet activating factor. Eight healthy men were studied in a randomised, double blind placebo controlled crossover study. A single dose of platelet activating factor that caused a fall of at least 35% in specific airways conductance (sGaw) was determined initially for each subject. Challenge with this dose of platelet activating factor was then carried out on two further occasions after pretreatment with a single nebulised dose of SK&F 104353-Z2 or placebo. The % reductions in specific airways conductance and of partial flow at 30% of vital capacity (PVmax30) were less after SK&F 104353-Z2 than after placebo (22 versus 34 for sGaw, 19 versus 31 for PVmax30). The mean (95% confidence limits (CL)) differences in the maximum % fall from control values for SK&F 104353-Z2 and placebo were - 12-6 (-23-8, -14) for sGaw and -12-5, (-20-8 -4 2) for PVmax30. The mean % fall in neutrophil count was similar after SK&F 104353-Z2 (46%) and after placebo (50%) (95% CL of difference 13-6, 6 6) . Bronchial responsiveness to methacholine did not increase above baseline values in any subject when measured two weeks after challenge by platelet activating factor. This study suggests that leukotrienes play a part in the response to platelet activating factor in man.
Asthma has an important inflammatory component, in which numerous mediators may play a part.' Complex interactions between mediators have been reported,2-5 and these, by amplifying the effects of individual mediators, could cause bronchial responsiveness to be increased.'
The cysteinyl leukotrienes and platelet activating factor (PAF) cause acute bronchoconstriction and increased bronchial responsiveness in various animals, and may be important mediators in asthma.' Inhaled PAF causes acute bronchoconstriction in man, a transient fall in circulating neutrophils, flushing, and a desire to cough.9"' Leukotriene D4 is one of the most potent naturally occurring bronchoconstrictors known, being up to 6000 times more potent than histamine." A prolonged increase in bronchial responsiveness has been reported to follow inhalation of PAF in normal subjects9 and of leukotriene E4 in asthmatic subjects.'2
The effects of PAF may depend on secondary leukotriene production. Human eosinophils produce large amounts of leukotriene C4 when stimulated by PAF," and PAF induced mucus production in human airways is reduced by a 5-lipoxygenase inhibitor in vitro. ' The subject took 10 inhalations of diluent (human serum albumin 2 5 mg/ml in 0 9% saline) from a Microneb III nebuliser (Lifecare Hospital Supplies Ltd, Market Harborough, Leicester) attached to a Nebicheck dosimeter (PK Morgan) by tidal breathing while wearing a nose clip. Control measurements of sGaw were made at one minute and of PVmax30 (mean of five values) at three minutes; venous blood was obtained for a differential white cell count at five minutes. The dosimeter was driven by air at 204 kPa (301b/in2) with a flow to the nebuliser of 8 I/ min. The volume median diameter of the aerosol particles was 4-5 ,um, and gravimetric assessment showed the nebuliser output to be 6-4 x 10-3 ml per actuation,3' giving a predicted dose of PAF of 9 6 x l0 mol per 10 inhalations.
Two millilitres of the PAF solution was placed in the nebuliser reservoir and 10 inhalations were taken as described for diluent. The ECG was monitored continuously and blood pressure measured (automatic sphygmomanometer) on completion of the inhalation. Measurements of sGaw (mean of eight values) were made at one and six minutes, and of PVmax30 (mean of two values) at three and eight minutes. Venous blood was obtained for a white cell count at five minutes. If the maximum mean fall in sGaw was less than 35% of the control value, the challenge was repeated two weeks later with 20 inhalations of the same concentration of PAF. Subjects were excluded from further study if bronchoconstriction did not occur at the higher dose because of the potential adverse cardiovascular effects of large doses of PAF. PROTOCOL Bronchial responsiveness to methacholine was assessed initially (baseline), and repeated two weeks after each PAF challenges. After the bronchoconstricting dose of PAF had been determined the PAF challenge was repeated on two treatment days, at least two weeks apart, after prior inhalation of either SK&F 104353-Z2 or placebo in a randomised, double blind, crossover study design. The methacholine challenge test was at least 24 No symptoms were reported by any subject after inhalation of either SK&F 104353-Z2 or placebo. The mean volume of solution nebulised was 1-7 ml (SD 0 40, range 1-2-2-6 ml), equivalent to 680 (range 480-1040) ug of SK&F 104353-Z2. There were no significant changes in pulmonary function after SK&F 104353-Z2 or placebo (table 1) .
There was a fall in sGaw, PVmax30, and circulating neutrophil count after PAF challenges on the two treatment days (figure). The maximum fall after SK&F 104353-Z2 was less than that seen after placebo for sGaw (22% v 
METHACHOLINE RESPONSIVENESS
Bronchial responsiveness to methacholine two weeks after each PAF challenge did not change by more than one doubling concentration of methacholine from baseline values in any subject. There was a trend for PC35sGaw and PC,0 PVmax30 methacholine to be higher two This study did not examine the possibility that bronchial responsiveness was increased at an earlier time after inhaled PAF because, in a previous study,"3 we were unable to find any significant increase in bronchial responsiveness at any time after PAF inhalation. Bronchial responsiveness was measured two weeks after each PAF challenge in the present study to ensure that baseline responsiveness was unchanged before the next treatment day. No changes in bronchial responsiveness were found at this time, in agreement with our previous findings and those of other workers, who had used various doses of PAF.3'37 The doses of PAF used in our study (9 6 x 10-8 mol or 19 x 10-mol) are similar to the geometric mean dose (11 x 10-mol) used in the study in which increased bronchial responsiveness occurred for up to four weeks after PAF inhalation in normal subjects.9 There must now be some doubt that such a prolonged increase in bronchial responsiveness is a reproducible consequence of PAF inhalation in normal subjects.
The mode of action of PAF in man has not been completely determined. Indirect mechanisms may be important, as shown by the finding that PAF induced contraction of human bronchial smooth muscle is platelet dependent in vitro,'8 and that pretreatment with an antihistamine reduces PAF induced bronchospasm in vivo.39 High affinity binding sites, which may represent specific PAF receptors, have been described in human lung homogenates.40 Bind- ing of PAF to these receptors may trigger complex intracellular transduction mechanisms that include activation of G proteins and protein kinase C, increased turnover of inositol phosphates, and a rise in intracellular Ca2+ Phospholipase A2 may then be activated, releasing arachidonate from membrane phospholipids with the subsequent production of a cascade of mediators, including leukotrienes, prostaglandins, and thromboxane. 4 
